1. Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth Military Medical University Xi’an, China

2. Background: FIREMAN at 1-Year

3. Study Design

4. FIREMAN Registry Prospective, Multicenter and Nationwide 45 Medical Centers

5. Patient Eligibility

6. Study Algorithm Patient enrollment (2006.09-2007.07) n = 1078 Excluded pts due to hybrid stenting, n=49 (4.5%) Clinical follow-up Angiographic follow-up 12months 97.2% (1001/1029 pts) 8 months 51% (517/1013pts) Primary End Point : MACE@ 12months Secondary End Point ： Binary Restenosis, Late loss at 8months, TVR, Stent thrombosis, Stroke 1029 pts Enrolled Diabetes 22.8% 24months 97.7% (1005/1029 pts ）

7. Frequency of Complex Coronary Lesions Criteria* % * Criteria are not mutually exclusive.

8. MACE @ 24 months (10) (12) (40) (36) (60) (2)

9. MACE-free Survival Rate 1.00 0 0.96 0.98 0.94 0.92 0.90 150 300450600 Mace-free Survival rate,% Days after Procedure 94.2%

10. TLR-free Survival Rate 0.92 0.90 1.00 0.94 0.92 0.98 0 600750450300 150 TLR-free Survival rate % Days after Procedure 95.9%

11. MI-free Survival Rate,% Days after Procedure 1.00 0.92 0.94 0.96 0 0.90 0.98 450300150 750 600 98.8% MI-free Survival Rate

12. Cardiac death-free Survival Rate,% Days after Procedure 1.00 0.98 0.96 0.94 0.92 0.90 1500 450300 750 600 99.0% Cardiac death-free Survival Rate

13. Stroke @ 2-Year %

14. Dual Anti-platelet Therapy 30d 6mo 12mo 18mo 24mo %

15. Stent Thrombosis @ 2-Year 0.92 0.90 1.00 0.94 0.92 0.98 0 600750 45 0 300 150 Stent Thrombosis-free Survival rate, % Days after Procedure 98.1%

16. 4 cases ST were due to prematurely stopping dual anti-platelet therapy before 12 months. 1 case of VLST due to prematurely stopping dual anti-platelet therapy before 12 months. DualASA alone

17. Cumulative Incidence of Stent Thrombosis 3 0 5 2 1 4 0 720540360 180 Stent Thrombosis Cumulative incidence, % Days after Procedure 1.55% 0.39%

18. Subgroup Analysis

21. Predictors of Cumulative Stent Thrombosis By Cox Regression Analysis VariablesHR(95%CI)P value Clinical variables Pre-MI2.776(1.007 ~8.329)0.211 Pre-PCI1.837(0.421~5.522)0.669 Hypercholesterima0.642(0.398~3.074)0.328 hypertension2.189(0.833~4.578)0.851 Diabetes8.651(2.393~21.543)0.008 Lesion characteristics Multi-vessel0.724 (0.152~2.299)0.416 Diffuse long2.023(0.898~6.244)0.347 Small vessel6..262(1.699~15.458)0.026 CTO5.171(1.881~12.369)0.035

22. J-CypherTaxusVIEndeavorIVFIREMAN DES Events CypherTaxusEndeavorFirebird Death1.700.51.50.97 MI3.608.82.01.17 TVR-13.98.93.50 TLR7.99.75.94.08 ST2.430.50.11.94 Total MACE -21.39.85.83 Comparison with other DES

23. Conclusions (1) 2-Year Efficacy ： 2-Year outcomes showed that FIREBIRD SES was effective and safe in the treatment of selectively complex lesions. 2-Year outcomes showed that FIREBIRD SES was effective and safe in the treatment of selectively complex lesions. 2-Year Safety ： No significant increase in very late stent thrombosis at 2 Years. No significant increase in very late stent thrombosis at 2 Years.

24. Conclusions (2) Very Late Stent Thrombosis Although the study population was a selective complex subsets, very late stent thrombosis was low at 0.39%. Diabetes, small vessel and CTO are still strongest predictors of stent thrombosis.. There was one case of VLST event in patients due to discontinuation of DAPT before 12 months.